EUVIMEDEUVIMED entdecken
Crossref

To contrast or not to contrast? Evaluating the diagnostic accuracy of hepatobiliary contrast agents in liver FDG-PET/MR: a prospective study

Luigi Asmundo iD, Felipe Furtado iD, Francis Delaney iD, Mojtahed Amirkasra iD, Azadeh Hajati iD, Abdar Esfahani Shadi iD, Avinash Kambadakone iD, Lawrence Blaszkowsky iD, Jeffrey Clark iD, David Ryan iD, Onofrio Antonio Catalano iD

European Journal of Nuclear Medicine and Molecular Imaging · 2025-10 · 52 (12) · 4582-4590

DOI: 10.1007/s00259-025-07333-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 09.05.2025. Verfasst von Luigi Asmundo und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, ASST Grande Ospedale Metropolitano Niguarda, Piazza Ospedale Maggiore 3, Milan, 20162, Italy. Hauptthemen laut MEDLINE: Fluorodeoxyglucose F18, Contrast Media, Liver Neoplasms, Magnetic Resonance Imaging. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: The role of hepatobiliary contrast-enhanced imaging in the evaluation of liver malignancies in FDG-PET/MR remains underexplored. The aim of this study was to assess the diagnostic performance of stand-alone FDG-PET, non-contrast-enhanced (NCE) PET/MR, and contrast-enhanced (CE) PET/MR with and without hepatobiliary phase (HBP). METHODS: This prospective, single-center diagnostic accuracy study enrolled 60 patients with histologically confirmed abdominal malignancies and malignant liver lesions. Each patient underwent whole-body FDG-PET/MR, including dedicated upper abdominal imaging with NCE, CE without HBP, and CE with HBP. Three blinded radiologists independently evaluated the images in consensus. The reference standard was histopathology or follow-up imaging. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and diagnostic accuracy were calculated. Fisher's exact test and Mann-Whitney U test were used for statistical comparisons. RESULTS: A total of 134 malignant liver lesions (38 primary tumors, 96 metastases) were identified. CE FDG-PET/MR with HBP achieved the highest diagnostic accuracy (97%), sensitivity (97.8%), and specificity (95.2%). NCE FDG-PET/MR had an accuracy of 67%, sensitivity of 78%, and specificity of 44%, while stand-alone FDG-PET had the lowest accuracy (52%). The addition of HBP significantly improved specificity (75.6-95.2%, p = 0.013) and enabled detection of smaller lesions (median size 7 mm vs. 19 mm, p = 0.00017). CONCLUSION: The inclusion of hepatobiliary contrast significantly enhances the diagnostic performance of FDG-PET/MR for liver malignancies, particularly in detecting small or poorly defined lesions. These findings support the integration of HBP into PET/MR workflows to optimize liver lesion detection and staging. CLINICAL TRIAL NUMBER: Not applicable.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fluorodeoxyglucose F18Contrast MediaLiver NeoplasmsMagnetic Resonance ImagingPositron-Emission TomographyMultimodal ImagingLiverHumansFemaleMaleMiddle AgedAgedProspective StudiesAdultAged, 80 and overSensitivity and SpecificityRadiopharmaceuticals

Stichwörter der Autor:innen

Diagnostic accuracyHepatobiliary contrastHepatobiliary phase MRILesion detectionLiver malignanciesOncologic imagingPET/MR imaging

Substanzen

Fluorodeoxyglucose F18Contrast MediaRadiopharmaceuticals

Autor:innen und Institutionen

  • Department of Radiology, ASST Grande Ospedale Metropolitano Niguarda, Piazza Ospedale Maggiore 3, Milan, 20162, Italy.
  • Stephen M. Ross School of Business, University of Michigan, 701 Tappan Avenue, Ann Arbor, MI, 48109, USA.
  • Mater Misericordiae University Hospital, Eccles St, Phibsborough, Dublin, D07 R2WY, Ireland.
  • Department of Radiology, Massachusetts General Hospital, 55 Fruit Street, WHT 270, Boston, MA, 02116, USA.
  • Harvard Medical School, Boston, MA, USA.
  • Department of Oncology, Massachusetts General Hospital, 55 Fruit Street, WHT 270, Boston, MA, 02116, USA.

ORCID-Profile: Luigi Asmundo, Felipe Furtado, Francis Delaney, Mojtahed Amirkasra, Azadeh Hajati, Abdar Esfahani Shadi, Avinash Kambadakone, Lawrence Blaszkowsky, Jeffrey Clark, David Ryan, Onofrio Antonio Catalano

Zitieren

APA

Asmundo, L., Furtado, F., Delaney, F., Amirkasra, M., Hajati, A., Shadi, A. E., Kambadakone, A., Blaszkowsky, L., Clark, J., Ryan, D., & Catalano, O. A. (2025). To contrast or not to contrast? Evaluating the diagnostic accuracy of hepatobiliary contrast agents in liver FDG-PET/MR: a prospective study. European Journal of Nuclear Medicine and Molecular Imaging, 52(12), 4582-4590. https://doi.org/10.1007/s00259-025-07333-9

Vancouver

Asmundo L, Furtado F, Delaney F, Amirkasra M, Hajati A, Shadi AE, et al. To contrast or not to contrast? Evaluating the diagnostic accuracy of hepatobiliary contrast agents in liver FDG-PET/MR: a prospective study. European Journal of Nuclear Medicine and Molecular Imaging. 2025;52(12):4582-4590. doi:10.1007/s00259-025-07333-9

BibTeX
@article{Asmundo2025,
  author = {Asmundo, Luigi and Furtado, Felipe and Delaney, Francis and Amirkasra, Mojtahed and Hajati, Azadeh and Shadi, Abdar Esfahani and Kambadakone, Avinash and Blaszkowsky, Lawrence and Clark, Jeffrey and Ryan, David and Catalano, Onofrio Antonio},
  title = {To contrast or not to contrast? Evaluating the diagnostic accuracy of hepatobiliary contrast agents in liver FDG-PET/MR: a prospective study},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2025},
  volume = {52},
  number = {12},
  pages = {4582--4590},
  doi = {10.1007/s00259-025-07333-9}
}
Kostenlos starten →